9920 Pacific Heights Boulevard
Suite 350
San Diego, CA 92121
United States
858 704 4660
https://www.vikingtherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 28
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Brian Lian Ph.D. | President, CEO & Director | 987.1k | N/A | 1966 |
Mr. Gregory S. Zante | Chief Financial Officer | 655k | N/A | 1971 |
Ms. Marianne Mancini | Chief Operating Officer | 670k | N/A | 1965 |
Mr. Michael Morneau | Vice President of Finance & Administration | 375.33k | N/A | 1965 |
Dr. Geoffrey E. Barker Ph.D. | Senior Vice President of Pharmaceutical Development | N/A | N/A | N/A |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Viking Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 8; Compensation: 8.